**
In a striking revelation, internal records indicate that top officials at the Environmental Protection Agency (EPA) met with Bayer’s CEO, Bill Anderson, to discuss legal strategies regarding the company’s controversial glyphosate-based herbicides. This meeting, which took place on 17 June 2025, has raised concerns about the extent of corporate influence over regulatory decisions, particularly in light of ongoing litigation involving allegations that Bayer’s products contribute to cancer.
High-Stakes Meeting with EPA Officials
The meeting between Anderson and key EPA figures occurred as Bayer faced mounting lawsuits from thousands of individuals claiming that their health was compromised due to the use of glyphosate products like Roundup. These lawsuits centre on accusations that Bayer neglected to provide adequate warnings about the associated cancer risks, despite numerous studies highlighting the potential dangers of glyphosate.
The discussions at the EPA were reportedly aimed at exploring various legal and judicial issues related to the ongoing litigation. A planning email from 13 June indicated that the agenda would include “supreme court action,” suggesting that Bayer sought to leverage governmental support to bolster its legal standing.
The Trump Administration’s Alignment with Bayer
Since the meeting, the Trump administration has taken significant steps to advocate for Bayer’s position. In December 2025, Solicitor General D John Sauer, appointed by the Trump administration, urged the Supreme Court to take up Bayer’s case, which they subsequently agreed to hear. This move, along with the invocation of the Defense Production Act to safeguard glyphosate production, demonstrates a clear alignment between federal actions and Bayer’s interests.
Bayer has maintained that their meeting with EPA officials was a routine part of the regulatory process and insists that they have been open about their legal challenges. However, this assertion has been met with skepticism by critics who argue that the meeting signifies a troubling trend of corporate power overshadowing public health concerns.
Voices of Concern
Nathan Donley, the environmental health science director for the Center for Biological Diversity, expressed alarm over the implications of such high-level meetings. He remarked, “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans.” This sentiment is echoed by legal experts and public health advocates who question whether ordinary citizens receive the same access to regulatory discussions as corporate leaders do.
Whitney Di Bona, an attorney focused on consumer safety, highlighted the imbalance of power, stating, “It’s concerning that the CEO of a major pesticide company can have private meetings with the EPA to talk about limiting the company’s liability.” Advocates argue that this dynamic raises ethical questions about the prioritisation of corporate interests over the welfare of the public.
A Pattern of Corporate Access
The meeting with Bayer is not an isolated incident but rather part of a broader pattern where industry leaders have privileged access to government officials. Naomi Oreskes, a professor from Harvard University, noted that this trend raises significant concerns regarding the integrity of regulatory processes. “When industry leaders have access to decision-makers in a way that citizens do not, it calls into question the fairness of the system,” she stated.
Zen Honeycutt, founder of Moms Across America, voiced her dismay over the situation, stating, “Coercion by chemical companies on our regulatory agencies is nothing new.” She expressed frustration at the lack of responsiveness from the EPA regarding calls for stricter regulations on harmful pesticides.
Why it Matters
The intersection of corporate interests and regulatory action has profound implications for public health and safety. As Bayer’s legal battles unfold, the revelations surrounding the EPA meeting raise critical questions about the integrity of the regulatory process. The balance between supporting industry and protecting the health of citizens must be scrutinised, as the consequences of prioritising profit over safety could have lasting effects on millions of Americans. The ongoing discourse surrounding glyphosate and its implications for human health serves as a poignant reminder of the need for transparency and accountability in regulatory decision-making.
